MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02671nam a22003377a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180818s20182018 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0169-5002 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1016/j.lungcan.2018.07.006 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
S0169-5002(18)30464-1 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
30089599 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. [Review] |
| 251 ## - Source |
|---|
| Source |
Lung Cancer. 123:76-82, 2018 Sep. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Lung Cancer. 123:76-82, 2018 Sep. |
| 253 ## - Journal Name |
|---|
| Journal name |
Lung cancer (Amsterdam, Netherlands) |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2018 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2019 |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2018-08-16 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Copyright (c) 2018 Elsevier B.V. All rights reserved. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
MET exon 14 mutation is an uncommon genomic alteration in non-small cell lung cancer (NSCLC). This meta-analysis aimed at investigating the clinicopathological and prognostic features of NSCLCs with MET exon 14 mutation in comparison with other genetic events. We performed a search in four electronic databases including PubMed, Web of Science, Scopus, and Virtual Health Library from inception to February 2018. Relevant data were extracted and pooled into odds ratio (OR), mean differences (MD), and corresponding 95% confidence intervals (CI) using the random-effect model. From 168 studies, we included 12 studies comprising of 18,464 NSCLCs for final analyses. Overall, the prevalence of MET exon 14 mutation in NSCLC was 3% (95% CI=2-3), with being most commonly found in pulmonary sarcomatoid carcinoma (13%; 95% CI=4-21). The mutation was more likely to occur in females (OR=0.55; 95% CI=0.33 - 0.90), patients with advanced age (MD=7.48; 95% CI=3.99-10.98), non-smoker (OR=0.48; 95% CI=0.28 - 0.83), and was associated with a worse prognosis (HR=1.82; 95% CI=1.04-3.19). Patients with MET exon 14 mutation had a distinct clinicopathological profile compared to other NSCLC genetic events. To summarize, MET exon 14 is a rare mutation in NSCLC and might be associated with a dismal survival. Patients harboring MET exon 14 skipping are eligible for targeted therapy with c-MET inhibitors, thus emphasizing the need to screen for this mutation in advanced NSCLCs. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Union Memorial Hospital |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Medicine |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Ho, An Thi Nhat |
| 790 ## - Authors |
|---|
| All authors |
Altibi AMA, Ho ATN, Katoh R, Kondo T, Nakazawa T, Vuong HG |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1016/j.lungcan.2018.07.006">https://dx.doi.org/10.1016/j.lungcan.2018.07.006</a> |
| Public note |
https://dx.doi.org/10.1016/j.lungcan.2018.07.006 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
